Skip to main content
SOLV logo

SOLV · Solventum Corp

Track SOLV — free
$87.77 -0.38 (-0.43%) At close · Oct 1
Market Cap
$15.24B
Shares
170.22M
Volume · Oct 1 784.53K Avg daily vol (3M) 1.03M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$87.77 Open$87.82 Day$86.26–88.55 52W close$62.49–92.44 Avg vol 30d884K Short int4.9M · 2.9% float · 5.7d Short vol64% Last earningsAug 5, 2026 DataMar 2024–Oct 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 5 wks
filed Aug 5, 2026
call held Aug 5, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$8.31B
Trailing 12 months
Net income (TTM)
$1.43B
Trailing 12 months
Revenue growth YoY
+2.2%
Year over year
Operating margin
25.0%
Trailing 12 months
P / E (TTM)
10.8
Trailing earnings · reciprocal yield 9.3%
FCF yield
-0.8%
TTM · current market cap
Return on invested capital
18.5%
Trailing 12 months
Net cash
−$4.68B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.1%
Year over year · fewer shares
Price change (1Y)
+20.8%
Trailing year
Short interest
2.9%
Latest settlement · 5.7 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 16.4 · calm Equity put/call 0.57
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg −0%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 84%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −4%
trailing
6-month return +33%
trailing
YTD return +11%
this year
Relative strength +21%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $88 › 200d $78 — 50d above 200d
Institutional flow Flat
1 of 890 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.86% of float · ▲ +13.1% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
890 holders — mid 2-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Strong
Revenue growth +1%
Y/Y
Gross margin 53%
contracting
EPS growth +222%
Y/Y
Free cash flow $-10.0M
Valuation P/E 10.9
below peers
Buyback $1.0B
authorized
Balance sheet $4.2B
net debt
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −27%
past year
ATR 2.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Aug 5, 2026
Adjusted EPS · full year 2026 Non-GAAP Initiated $7.10 – $7.20
Free cash flow · full year 2026 Non-GAAP Initiated $200M – $300M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
1 · 5 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
−0% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
84% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross) No cross
50d $88 › 200d $78 — 50d above 200d
Institutional flow Flat
1 of 890 funds reported for Sep 30 · net 0 sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.86% of float · ▲ +13.1% MoM · 5.7 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
890 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $62 Now $88 · 84% Range high $92
vs 200-day avg +13% vs 50-day avg 0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Instruments & Supplies — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SOLV
Solventum Corp
this stock
$15.24B +10.8% +0.9% 10.9 2.9%
ISRG
Intuitive Surgical Inc
$143.14B -29.2% +20.5% 46.5 2.3%
BDX
Becton Dickinson & Co
$49.57B — +8.2% — 4.2%
MDLN
Medline Inc.
$45.62B -16.8% +11.5% — 3.1%
RMD
Resmed Inc
$32.02B -8.2% +13.4% 21.3 9.8%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
890
% held
75.3%
Reported
1 of 890
Top holder
Independent Franchise Par…
Held Float
View
Held by Funds
Fund positions
517
View
Short & Settlement
Short Interest Rising
Shares short
4.9M
Days to cover
5.7d
Change
+563.2K sh
View
Short Volume
Short vol %
64%
As of
Oct 1, 2026
Short Total
View
Fails to Deliver
FTD shares
106
Value
$9.3K
As of
Sep 11, 2026
View
Off-Exchange
Off-exchange %
45.4%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 27, 2026
View
Financials
Financials
Revenue (FY)
$8.3B
Net income (FY)
$1.6B
EPS diluted
$8.88
View
Buybacks
Authorized
$1.0B
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 5, 2026
This year
13
View
Earnings & Events
Webcasts
Last webcast
Aug 5, 2026
View

Performance

5D 20D 120D MTD YTD
SOLV -0.9% -4.5% +33.4% -0.4% +10.8%
SPY -0.4% -0.2% +12.4% +0.2% +12.0%
vs SPY -0.5% -4.3% +21.0% -0.6% -1.3%

Capital returns

Buyback program · as of Dec 16, 2025
Authorized
$1.00B
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1964738 CUSIP 83444M101 13F (30d) 33 filings 20 filers Visit website Investor relations